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To describe the spread of hepatitis C virus (HCV) among HCV/human immunodeficiency virus (HIV)–
coinfected injection drug users (IDUs), the molecular epidemiology of HCV was studied among 108 IDUs
from 7 European countries. Phylogenetic analysis based on the NS5B region showed great sequence variation
of HCV within each country and no clear phylogenetic clustering by geographic region. The most prevalent
subtypes were 1a and 3a, but the percentage of genotype 4 was also relatively high, ranging from 7% in
northern Europe to 24% in southern Europe. Genotype 4 consisted mainly of subtype 4d and has entered the
majority of the IDU populations studied. The significantly lower evolutionary distances within subtype 4d
suggest that this subtype may have entered the European IDU population relatively recently. In conclusion,
HCV exchange between European IDU populations has occurred on a large scale, and, overall, country-specific
clustering for HCV was less than that shown for HIV.
Because of the use of contaminated needles and injec-
tion equipment, injection drug users (IDUs) are an
important risk group for acquiring hepatitis C virus
(HCV) infection [1–3]. Although symptoms in the
acute phase of infection are usually absent or mild, up
to 85% of those infected develop chronic hepatitis C
[1, 4–6], and, over several decades, serious symptoms,
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such as liver cirrhosis and hepatocellular carcinoma,
may develop [7, 8]. IDUs are also a well-known risk
group for infection with HIV, which is also transmitted
through parenteral exposure, albeit much less efficiently
than is HCV [1]. Coinfections with both viruses are
common in IDUs [9, 10], with HCV-related liver dis-
ease becoming more evident among coinfected indi-
viduals in the recent years, since anti-HIV treatment
has led to increased life expectancy [11, 12]. As is the
case for HIV, the genome of HCV is highly variable
because of the lack of proofreading activity during virus
replication [13]. HCV is classified into 6 different ge-
notypes, each consisting of different subtypes. The dif-
ferent genotypes are known to differ in their distri-
bution, depending both on geographic region and on
mode of transmission [14]. Of the different HCV sub-
types, 1a and 3a are the predominant subtypes among
IDUs in Europe [15–17]. HCV is one of the few mi-
croorganisms for which genotyping, besides providing
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epidemiological information, also provides information with
regard to treatment [18]. In the case of infection with genotype
2 or 3, treatment is more often successful than in the case of
infection with one of the other genotypes [14, 18–20].
From a public health perspective, it is important to know how
both viruses spread between IDUs. Very few studies have ad-
dressed this issue on a European level. For HCV, one study
determined the extent of transmission of subtypes 1a and 3a
among several cities, most of which were in the United Kingdom,
but the study also included Marseille, France, which is on the
mainland of Europe, and Melbourne, Australia. It showed that
none of these cities had a virus population that was completely
isolated from that circulating in another city. Some regional
differences were observed—mainly that the virus strains from
London were the most phylogenetically dispersed [21]. For
HIV, a study including a greater diversity of European cities
showed that the genetic relatedness differs between several
European countries [22]. The HIV epidemic was relatively
conserved among IDUs in Edinburgh but was relatively diverse
among IDUs in The Netherlands, Austria, and Switzerland,
most likely due to multiple virus introductions and, perhaps,
IDUs with more international contacts. Furthermore, geo-
graphical separation between HIV epidemics in northwestern
Europe and those in southwestern Europe has faded over
time, probably due to virus exchange between IDU populations.
For HCV, the genetic relatedness has not yet been studied in
such a diverse group of cities across Europe, and that HCV
and HIV share the same transmission route does not necessarily
mean that the pattern of spread of HCV is similar to that found
for HIV.
Since very little is known about the migration of HCV among
IDUs across Europe or how it compares with that of HIV, we
investigated both the genotype distribution and the genetic links
of the HCV strains circulating among different European IDU
populations coinfected with HCV and HIV. These are the same
IDU study populations for which the molecular epidemiology
of HIV has been studied previously, which thereby allows a
comparison of the phylogenies of both viruses [22].
SUBJECTS, MATERIALS, AND METHODS
Study subjects and samples. For this study, serum samples
from 183 HIV-1–positive European IDUs were available. The
samples were collected as part of the European and Italian
Seroconverter Studies [22] from sites in Austria (Innsbruck,
), Italy (Reggio Emilia and Turin, ), The Neth-np 24 np 15
erlands (Amsterdam, ), Scotland (Edinburgh and Glas-np 31
gow, ), Spain (Alicante and Castellon, ), Swit-np 41 np 30
zerland (Geneva, ), and France (Paris, Marseille, andnp 22
Nice, ). The samples were collected between 1984 andnp 20
2001, mostly within 1–3 years after HIV seroconversion (table
1). A study of the phylogeny of HIV was performed previously
on these same samples [22].
Serologic testing. Samples were tested for the presence of
antibodies against HCV by use of a commercial EIA system
(Monolisa anti-HCV plus, version 2; BioRad). The assay was
performed in accordance with the manufacturer’s instructions.
No confirmation testing was performed.
RNA isolation. RNA isolation was performed on all sam-
ples containing at least 100 mL of serum. To increase the yield
of RNA-positive samples, we used 2 isolation methods. First,
isolation was performed by use of the QIAamp viral RNA mini
kits (Qiagen; Westburg). If no RNA was detected by polymerase
chain reaction (PCR), isolation was performed again, by use
of the TriPure method. The pellets were resuspended in a vol-
ume of 50 mL containing 10 mmol/L Tris HCl [pH 8.0] and
10 U of RNasin (Roche Diagnostics). Both the QIAamp and
the TriPure isolation procedures were performed in accordance
with the manufacturer’s instructions. All RNA samples were
stored at 80C until amplification.
Reverse-transcriptase (RT) PCR. An RT-PCR targeting the
core region of the HCV genome was performed on all the
samples. This PCR was used to test for the presence of HCV
RNA and to determine the HCV genotype present. On the
samples that tested positive by this PCR, a second RT-PCR was
performed, targeting the more-variable NS5B region, which was
used for phylogenetic analysis. Amplimers were detected and
analyzed on 10% acryl-amide gels (BioRad).
Core PCR. The RT-PCR targeting the core region was based
on the genotyping system described by Ohno et al. [23]. This
PCR was shown to detect all HCV genotypes [23]. For the first-
round PCR, the AccessQuick RT-PCR system (Promega Benelux)
was used, and 3 mL of sample was added to 22 mL of reaction
mixture, resulting in a volume of 25 mL containing 1 avian
myeloblastosis virus (AMV)/Thermus flavus buffer, 2 mmol/L
MgSO4, 200 mmol/L dNTPs, 400 pg/mL each primer, 2.5 U of
AMV RT, and 2.5 U of Tfl DNA polymerase. The PCR program
consisted of 45 min at 48C and 2 min at 94C, followed by
30 cycles for 30 s at 94C, 30 s at 55C, and 50 s at 68C and
a final incubation for 7 min at 68C. For the nested PCR, 2
mL of outer PCR product was added to 23 mL of reaction
mixture, resulting in a volume of 25 mL containing 1 PCR
buffer, 2 mmol/L MgCl2, 200 mmol/L dNTPs, 800 pg/mL each
primer, and 0.5 U of Taq polymerase (Eurogentec). The PCR
program used for the second-round PCR consisted of 5 min
at 94C, followed by 30 cycles for 30 s at 93C, 30 s at 55C,
and 1 min at 72C and a final incubation for 7 min at 72C.
In some samples, we found an additional band of ∼200 bp in
mix 1. These bands were not considered, assuming that they
were the result of aspecific cross-hybridization of the core prim-
ers, in case of a high virus load, as described elsewhere [23].
NS5B PCR. The PCR targeting the NS5B region of HCV
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Table 2. Primers used in polymerase chain reaction (PCR) tar-
geting the NS5B region of hepatitis C virus.
Primer Sequence (5′r3′)
Nucleotide
positiona
Specific for
genotype
A1b (O/S) CTGACRACTAGCTGYGGTAAYAC 8113–8135 1
F1b (O/A) CCTGGAGAGTAACTRTGGAGTG 8678–8699 1
B1b (I/S) GCTCCRGGACTGCACSATGCTCGTG 8181–8205 1
E1b (I/A) AATGCGCTRAGRCCATGGAGTC 8654–8675 1/4
2HCV-OS GTGTTCACCACYAGCATGGGGA 8110–8131 2
2HCV-OA WSAGTTCGTGGGGAGWGTATGT 8687–8708 2
2HCV-IS TGGTRTGTGGMGACGACYTGGT 8201–8222 2
2HCV-IA GCCCGTGTAGCCTTTCAATTAT 8644–8665 2
A3a (O/S) ACAATCACTTGTTACATCAAGGCC 8134–8157 3a
F3a (O/A) TCTACTGGAGAGTAACTGTGGA 8681–8703 3a
B3a (I/S) GGAACCCGGACTTTCTTGTC 8186–8205 3a
E3a (I/A) CCATGGAGTCTTTCAATGATTG 8642–8663 3a
4HCV-OS ACCACCAGCTTYGGRAACAC 8116–8135 4
4HCV-OA TTCGTGTGGAGAGTATCCRTGCA 8681–8704 4
4HCV-IS CTGAGAGACTGCACSATGYTGGT 8182–8204 4
NOTE. All primers are expected to show some degree of cross hybridi-
zation to targets of other genotypes. A, antisense; I, inner PCR; O, outer PCR;
S, sense.
a Numbered as in Choo et al. [31].
was based on the techniques of Mellor et al. [24] and Cochrane
et al. [21]. In addition, primers for genotypes 2 and 4 were
selected, since the core PCR, designed to detect all genotypes,
indicated the presence of these genotypes. The resulting frag-
ments of the NS5B region consist of 465–494 nt, depending
on the genotype. Table 2 shows an overview of the primers
used (all primers were obtained from Life technologies). The
RT-PCR targeting the NS5B region was performed under the
same conditions as those described for the core PCR (see pre-
vious paragraph), with the exception that, in the first-round
PCR, 1.5 mmol/L MgSO4 was used, and annealing of primers
took place at 45C.
Sequencing. For the sequencing reaction, samples that had
tested positive by NS5B PCR were ethanol precipitated. Both
the sense and antisense strands were cycle-sequenced by use of
the BigDye Terminator (BDT) system (versions 2.0 and 3.0;
Perkin Elmer Benelux). For both the BDT reaction mixtures
and the PCR program, the manufacturer’s instructions were
followed, with the adjustment of using 2 mL of reaction reagent
(RR) mix combined with 2 mL of RR buffer, instead of 4 mL
of RR mix. Subsequently, the products were purified by use of
DyeEx spin kits (Qiagen; Westburg), in accordance with the
manufacturer’s instructions. Analysis of the sequencing prod-
ucts was performed on an Applied Biosystems 310 automated
sequencer (Applied Biosystems).
Phylogenetic analysis. The obtained sequences were aligned
in the BioEdit sequence alignment editor [25] either by visual
inspection or using ClustalW Multiple alignment [26]. Phylo-
genetic trees for HCV were based on 425 nt of the NS5B region,
and, for HIV, trees were based on env sequences published
elsewhere [22]. Neighbor-joining trees and evolutionary dis-
tances were calculated with MEGA software (version 2.1) [27],
by use of the Tamura-Nei substitution model with g distri-
bution ( for HCV and for HIV [28, 29]).ap 0.40 ap 0.38
To analyze the stability of the tree topology, bootstrap values
( ) were calculated. The degree to which HCV circu-np 1000
lating in one European region (northern, central, or southern)
was phylogenetically distinct from HCV circulating in another
European region was measured in terms of an association in-
dex (AI), as described elsewhere [21, 30]. In brief, the degree
of phylogenetic mixing of defined groups (in this case, se-
quences from different geographic regions) is scored in a phy-
logenetic tree. This value is then compared with the score
from a tree with the same topology, but with the sequences
randomly relocated at the tips of the tree; the ratio of the
observed score to the control score produces the AI. AI values
approaching zero represent almost-complete segregation of se-
quences, whereas values of 1 suggest complete phylogenetic
mixing (i.e., no more segregation between the regions than
would be expected by chance). Bootstrap resampling of the
original sequence data is used to determine the confidence
intervals of the association values obtained. The AI method was
also used to compare the HCV and HIV phylogenies. The
method can be used for the comparison of different genome
regions or different organisms, since it is designed to look at
the relative positions of sequences in relation to the nodes and
does not consider branch lengths.
Statistical analysis. Differences between groups were
tested by either the Student’s t test or the x2 test, by use of the
SPSS statistical software package (version 9.0).
Sequence accession numbers. The obtained sequences
were submitted to GenBank and given the following accession
numbers: AY131338–AY131435.
RESULTS
Subject characteristics. The median age of the 183 European
HIV-positive IDUs was 29 years (interquartile range [IQR], 25–
34 years); 65 (36%) of the IDUs were female. The drugs most
commonly injected were heroin or heroin plus cocaine. Samples
were collected between 1984 and 2001. The median time be-
tween the initiation of injection drug use and the date of sam-
pling was 9 years (IQR, 5–13 years). Not all samples contained
enough volume to allow both antibody and RNA testing. The
presence of HCV antibodies was tested for 180 IDUs, of whom
170 (94.4%) tested positive. For the individual study sites, the
percentage that tested positive for antibodies ranged from 83%
to 100% (table 1).
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Table 3. Hepatitis C virus genotype distribution by geographic
region.
Genotypea
Geographic region
Overall
Northern
Europe
Central
Europe
Southern
Europe
1a 13 (44.8) 11 (25.0) 17 (41.5) 41 (36.0)
1b 2 (6.9) 5 (11.4) 6 (14.6) 13 (11.4)
3a 10 (34.5) 20 (45.5) 8 (19.5) 38 (33.3)
4 2 (6.9) 4 (9.1) 10 (24.4) 16 (14)
Not typeable 2 (6.9) 4 (9.1) 0 6 (5.3)
Total 29 (100) 44 (100) 41 (100) 114 (100)
NOTE. Data are no. (%) of subjects. Northern Europe: Amsterdam, Ed-
inburgh, and Glasgow; central Europe: Innsbruck, Paris, Geneva, Turin, and
Reggio Emilia; southern Europe: Marseille, Nice, Alicante, and Castellon.
a The strains found in 6 HCV double infections are included separately in
the genotype distribution. These included 1 injection drug user (IDU) with 1b
and 4 (northern Europe), 1 IDU with 1b and 3a (central Europe), 3 IDUs with
1b and 4 and 1 IDU with 3a and 4 (southern Europe).
HCV RNA prevalence and genotype distribution. Of the
170 samples positive for HCV antibody, core PCR analysis was
performed on 150 samples, of which 103 (68.7%) tested positive
for HCV RNA. Irrespective of antibody status, the total number
of samples that tested positive by core PCR was 108, in which
114 strains were detected, including 6 samples with HCV dou-
ble infections. Genotyping showed that the European HIV-
positive IDUs are most commonly infected with HCV subtypes
1a and 3a and, to a lesser extent, with genotype 4 and subtype
1b. Genotypes 2, 5, and 6 were not found in our study pop-
ulation. The genotype distribution established by the core PCR
was the following: 1a, 36.0%; 1b, 11.4%; 3a, 33.3%; 4, 14.0%;
and 5.3% could not be typed. Six persons had an HCV double
infection: 4 persons were infected with both type 1b and type
4, 1 person with 3a and 4, and 1 with 1b and 3a (table 3). The
prevalence of the different genotypes varied by geographic re-
gion. Geographic region was categorized as northern Europe
(Amsterdam, Edinburgh, and Glasgow), central Europe (Inns-
bruck, Paris, Geneva, Turin, and Reggio Emilia), and southern
Europe (Marseille, Nice, Alicante, and Castellon). In northern
and southern Europe, genotype 1a was the most prevalent ge-
notype (44.8% and 41.5%, respectively), whereas, in central
Europe, genotype 3a dominated (45.5%). From northern to
central to southern Europe, the prevalence of genotype 1b in-
creased (6.9%, 11.4%, and 14.6%, respectively), although not
significantly ( , x2 test). In contrast, the increasing trendPp .32
from northern to central to southern Europe for genotype 4
was significant (6.9%, 9.1%, and 24.4%, respectively; ,Pp .03
x2 test). Comparing the genotype distributions of earlier versus
later samples for each geographic region separately (the cutoff
for earlier vs. that for later, defined as sample dates below or
above the median), showed no significant differences. However,
it must be noted that, for this subanalysis, numbers were small
because of the extra categorization for calendar period.
NS5B PCR. Of all samples that tested positive for HCV
RNA by core PCR, 98 sequences were obtained after a second
PCR, which targeted the more-variable NS5B region. Com-
parison of genotyping based on the core region and genotyping
based on sequencing of the NS5B region showed a high level
of concordance: the results of the 2 methods were in agreement
for 88 comparisons (91.7%). The main difference was that only
2 HCV double infections were detected by sequencing of the
NS5B region, versus 6 by core PCR. This is to be expected,
since core PCR is designed to detect all the genotypes present,
whereas, in the case of an HCV double infection, sequencing
of the NS5B region will most likely detect the genotype that is
present at the highest concentration.
NS5B phylogenetic analysis. In total, 98 sequences of the
NS5B region were obtained from samples from 96 IDUs, since
2 HCV double infections were detected by sequencing of the
NS5B region. The phylogenetic tree was cut into 3 parts because
of its large size (figures 1A–1C). As can be seen in figure 1A,
all study sites are represented in the tree of genotype 1. Although
2 strains or small groups of strains from the same city can
sometimes be found located together in the tree, the overall
picture is very mixed. Especially strains from The Netherlands
and France are found throughout the tree. In the part of the
tree representing subtype 3a, strains from all cities are again
highly dispersed (figure 1B). For genotype 4, only 1 strain clus-
tered with the 4a reference strain (figure 1C). The other strains
clustered with the subtype 4d reference strain. Strains from
most countries are seen in this part of the tree, although the
strains from southern Europe dominate. Strains 108 and 109,
which are derived from 2 IDUs from Marseille who were broth-
ers, are identical and were both obtained on the same date.
Possibly, these IDUs had infected each other in the period close
to sample collection. The 2 subtype 4d strains from Amsterdam
originate from IDUs with foreign nationalities (Irish and Ger-
man). Compared with those of the other subtypes, the distances
between the different strains of subtype 4d are clearly smaller.
This is supported by the mean evolutionary distances (ex-
pressed as proportion of nucleotide difference), which are sig-
nificantly lower for subtype 4d than for 1a, 1b, or 3a (by use
of the Tamura-Nei substitution model; mean, 0.014 vs. 0.067,
0.055, and 0.047, respectively; , Student’s t test).P ! .001
Comparing HIV and HCV sequence diversity among Eu-
ropean IDUs. HIV sequences of the V3 region were available
for 145 IDUs from the same study population [22], partially
overlapping the 96 IDUs for whom we obtained HCV se-
quences. For the group of IDUs for whom both an HCV and
an HIV sequence were obtained ( ), both the HCV andnp 65
the HIV phylogeny are shown (figure 2). Comparing the phy-
logenies of these 2 viruses with the individual level indicates
that, in most cases, HCV and HIV do not seem to have been
Figure 1. Neighbor-joining tree based on the Tamura-Nei substitution model with a g distribution ( ). Bootstrap values higher than 70 areap 0.40
shown ( ). A, Hepatitis C virus (HCV) NS5B genotype 1. B, Hepatitis C virus NS5B genotype 3. C, Hepatitis C virus NS5B genotype 4.np 1000
Figure 2. Hepatitis C virus (HCV)/NS5B and HIV/env phylogeny. Neighbor-joining tree based on the Tamura-Nei substitution model with a g
distribution ( for HCV and for HIV [28, 29]). The HCV type is indicated next to the HIV tree.ap 0.40 ap 0.38
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Table 4. Association indices between different geographic
regions, for hepatitis C virus (HCV) subtypes 1a and 3a and HIV.
Region
Association indexa
HCV 1a HCV 3a HIV
Northern Europe and central
Europe 0.79 0.56 0.72
Northern Europe and southern
Europe 0.65 0.60 0.49
Central Europe and southern
Europe 0.68 1.05 0.59
NOTE. Northern Europe: Amsterdam, Edinburgh, and Glasgow; Central
Europe: Innsbruck, Paris, Geneva, Turin, and Reggio Emilia; southern Europe:
Marseille, Nice, Alicante, and Castellon.
a Measure of segregation between 2 groups of sequences. Values ap-
proaching zero represent almost complete segregation, whereas values of1
suggest no more segregation between the regions than would be expected
by chance [21, 30].
transmitted simultaneously or between the same individuals.
Concerning the degree of phylogenetic mixing for both viruses,
it seems that HIV sequences from the same city were more
often located together than were HCV sequences from the same
city, although differences between the trees are difficult to assess
visually. Therefore, for both HCV and HIV, the degree of phy-
logenetic mixing of the sequences in the different European
regions was measured by calculation of AI values (northern vs.
central, northern vs. southern, and central vs. southern Europe)
(table 4). This method allows the use of all available sequences
for each virus (HIV, 145 IDUs; HCV, 96 IDUs) and the quan-
tification of the degree of phylogenetic mixing. In general, the
AI values were somewhat higher for HCV than for HIV (higher
values reflecting a higher degree of phylogenetic mixing of virus
between 2 regions; table 4). For HCV subtype 3a, there is a
modest degree of sequence segregation between the sequences
from northern Europe and those from central and southern
Europe (AI, 0.56 and 0.60, respectively), whereas sequences
from central and southern Europe had an AI of 1.05, which
means that they were undifferentiated. Such a difference in the
degree of phylogenetic mixing between the sequences from
northern Europe and the sequences from central and southern
Europe was not found for subtype 1a, which showed a modest
degree of segregation of sequences from all the different Eu-
ropean regions (AI, 0.65–0.79). HCV subtypes 1b and 4d could
not be analyzed, because of the small numbers of sequences.
DISCUSSION
We have shown that transmission of HCV between IDU pop-
ulations from different European cities has occurred on a very
large scale, since strains from all the different European cities
are highly dispersed throughout the phylogenetic tree. Also, the
HCV epidemic within each European city is diverse, as multiple
strains of various subtypes circulate within each country. Over-
all, country-specific clustering for HCV was somewhat less than
that shown previously for HIV in this same study population.
Contrary to that for HIV, the HCV phylogeny showed no clear
division between epidemics in northwestern Europe and those
in southwestern Europe. Furthermore, the HCV-infected pop-
ulations in most cities were visibly phylogenetically dispersed,
whereas, in a study of HIV in this same study population, this
finding was shown only for Amsterdam, Innsbruck, and Geneva
[22]. Our finding that, for the most part, AI values were higher
for HCV than for HIV confirms a higher degree of HCV ex-
change in Europe. This lower degree of country- and region-
specific clustering for HCV could be due to the fact that, com-
pared with HIV, HCV entered the IDU population as soon as
injection drug use became popular in the late 1960s, which is
almost 2 decades before HIV entered this population [32, 33].
This, together with the fact that, during parenteral exposure,
HCV is transmitted up to 10-fold more efficiently than is HIV
[1], probably has allowed HCV to enter the IDU population
through more introductions than HIV and to have circulated
up to 20 years longer in this specific population. This may also
explain why directly comparing HCV phylogenies of IDUs for
whom sequences of both viruses were available with HIV phy-
logenies of the same IDUs does not indicate simultaneous trans-
mission of HIV and HCV in the majority of cases. In most
cases, HCV was probably already present before HIV infection
was acquired. For all IDUs included in the present study, the
most likely route of HIV infection reported was injection drug
use. However, we cannot completely rule out the possibility
that sexual transmission of HIV could play a role in the differing
patterns of HIV and HCV spread, since, unlike HCV, HIV is
also sexually transmissible, and the proportion at which these
2 transmission routes contribute to the transmission of HIV
in the present study population is not clear [34, 35]. A final
explanation could be that it has been well established that an
individual can be coinfected with 2 different HCV strains [36–
38] or acquire a new infection after clearing the first, whereas,
for HIV, this is thought to be less likely.
It has been shown that clearance of HCV occurs in ∼20%
of infected persons [39, 40]. This finding explains a major part
of the discrepancy between the number of subjects positive for
antibody and the number of subjects positive for RNA (68.7%
of those positive for antibody) found in the present study.
Different storage conditions and different cycles of freezing and
thawing, for earlier research purposes, may also have influenced
the sample quality, since the percentage of subjects positive for
HCV RNA varied largely by site of origin (36%–95%). The
overall proportion of samples positive by PCR is similar to that
found in the study of HIV conducted in the same study pop-
ulation (71%), with the variation by site being similar as well
[22]. Also, RNA-negative samples were stored a median of 3
years longer than were positive samples (sample years 1991 vs.
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stored samples from so many different countries were available
for the present study. Since it is to be expected that the age of
the samples would have some effect on detection of RNA, a
68.7% RNA-positivity rate for the samples positive for HCV
antibody can be considered to be a relatively good result.
As is the case for the general IDU population, the present
study has shown that, among HIV-infected IDUs, subtypes 1a
and 3a are the most prevalent subtypes [15–17]. No IDU in
our study was infected with genotype 2, 5, or 6. We did, how-
ever, find a relatively high percentage of infections with ge-
notype 4 (overall 14.0%), increasing from 6.9% in northern
Europe to 24.2% in southern Europe. Genotype 4 is predom-
inantly found in Africa, where it has been reported in countries
such as Cameroon, Gabon, the Central African Republic, and
Egypt, a country known for its extremely high prevalence of
genotype 4 infections [14, 41]. Although not all Egyptian studies
investigated subtype distributions, the majority of the type 4
infections further subtyped are subtype 4a [42], whereas, in
Saudi Arabia, subtype 4d is reported to circulate [43]. Recently,
genotype 4 has also been reported in low percentages in the
general populations, as well as among IDUs, of several Euro-
pean countries [17, 37, 44, 45]. Furthermore, genotype 4 was
found in 7.5% of hemodialyzed patients in a Belgian study and
in 5.2% of the general population of Vienna, Austria [17, 46],
but most prevalences of genotype 4 that are 15% are reported
in France and more-southern European countries [47–50]. In
the present study, all but 1 of the genotype 4 infections were
subtype 4d. Two of the studies reporting genotype 4 in Europe
also report subtype 4d [50, 51]. Our study has shown that
subtype 4d has entered the majority of the European IDU pop-
ulations studied. Scotland and Switzerland are the only coun-
tries in the present study in which subtype 4d was not detected,
but the number of RNA-positive samples from both countries
was low. Speculating on the origin of the specific subtype 4d,
which is now circulating among European IDUs, is difficult
with these data. We do know, however, that subtype 4d was
introduced into the IDU population at least 13 years ago, be-
cause 1 subtype 4d strain was derived from an IDU in Nice as
early as 1989. Also, in Marseille, Amsterdam, and Innsbruck,
subtype 4d strains were found in samples obtained early (1990
and 1991). To our knowledge, no other study has reported
genotype 4 in European IDUs as early as this. Perhaps, the high
prevalence of genotype 4 infections in southern Europe is due
to this region’s proximity to Africa. However, in the present
study, the samples derived from Spain were also the most recent
samples obtained (1996–1998), suggesting that, perhaps, the
high prevalence of genotype 4 in Spain may reflect an increasing
spread of genotype 4 among IDUs in recent years. Such an
effect of calendar time on the prevalence of genotype 4 would
be in accordance with the findings of 2 previous studies as-
sociating genotype 4 in Europe with recent transmission [17,
44]. In general, sequences tend to become more heterogeneous
over time, and, therefore, a recent spread of genotype 4 is also
supported by the fact that the subtype 4d strains in the present
study have significantly shorter evolutionary distances than the
other subtypes. Even among subtype 4d strains derived from
different countries, the similarity was great. This observation
also indicates that subtype 4d most likely did not enter the
IDU population by many introductions, since a greater se-
quence variation should otherwise have been observed. Because
of the extent of homogeneity of subtype 4d strains across Eu-
rope, we propose that genotype 4d was most likely introduced
into the European IDU population relatively recently by only
1 or a few introductions and was thereafter transmitted between
IDUs across European borders.
The distribution of HCV genotypes is of particular impor-
tance, since genotypes vary in their response to treatment, with
genotypes 1 and 4 showing lower success rates than genotypes
2 and 3 [14, 18]. This is of importance for southern Europe,
which is the region with the highest proportion of IDUs in-
fected with genotype 1 or 4 in the present study (81% in south-
ern Europe vs. 66% and 56% in northern and central Europe,
respectively). Prevention of HCV among IDUs has been shown
to be difficult [52, 53], as illustrated by a strong decline in the
incidence of HIV infection among IDUs in recent years that
has not been matched by a similar decline in the incidence of
HCV infection. Prevention campaigns, harm-reduction pro-
grams, and a shift to noninjection drug use apparently have
had less effect on transmission of HCV than on HIV, despite
the fact that, in IDUs, both viruses share the parenteral trans-
mission route [54–56]. Although they have not yet been in-
vestigated, differences between the 2 viruses, such as a higher
background prevalence of HCV among IDUs and its higher
transmission efficiency, may play a role in this phenomenon
[57]. In future efforts to prevent HCV infection among IDUs,
the high degree of virus exchange between IDUs across Eu-
ropean borders is an issue to consider.
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